logo
logo

Cumulus raises £3.25M to advance neuroscience clinical trials via at-home EEG-tech, led by Whiterock's Growth Capital Fund.

Jul 08, 2025•8 days ago

Amount Raised

£3.25 Million

BelfastMedicalBiotechnologyHealth Care

Investors

Co Fund NiAcf InvestorsClarendon Fund ManagersInvestment Fund For Northern IrelandWhiterock's Growth Capital Fund

Description

Cumulus Neuroscience has raised £3.25 million for its NeuLogic platform, aimed at improving neuroscience clinical trials. The funding, led by Whiterock's Growth Capital Fund, will help provide objective data in neurological assessments. The platform utilizes a novel dry sensor EEG headset for patient testing at home. This addresses the unmet need for objective brain function data in clinical studies.

Company Information

Company

Cumulus Neuroscience

Location

Belfast, Northern Ireland, United Kingdom

About

Cumulus Neuroscience is a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data. They are dedicated to developing breakthrough screening tests for early detection of Alzheimer's dementia, aiming to provide quicker and more accurate ways to diagnose dementia.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Related People